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Abstract
Background:  Co-trimoxazole use is the standard of  care for preventing Pneumocystis jirovecii pneumonia in sub-Saharan 
Africa but implementation remains slow. Co-trimoxazole is self- administered with uncertain adherence.   Knowledge of  
co-trimoxazole use among HIV infected persons is unknown.
Objectives:   To assess knowledge, attitudes and  practices of   co-trimoxazole use  among HIV infected adults evaluated for 
recurrent PTB in Kampala, Uganda.
Methods: A qualitative study utilizing 5 focus group discussions among 30 HIV infected PTB suspects at the national refer-
ral tuberculosis treatment centre in Kampala.
Results:  Males and females had similar median ages. 80% were currently on co-trimoxazole and 50% of  participants were 
on HAART. Majority of  participants defined co-trimoxazole as an analgesic. Few noted co-trimoxazole was a drug to treat 
cough and chest pain. However, few responses revealed that co-trimoxazole prevents opportunistic diseases among PLHIV. 
Most of  participants believed HAART and anti-TB drugs work as co-trimoxazole thus it should not be taken together with 
them. This belief  may lead to increased risk of  opportunistic infections, morbidity and mortality.
Conclusions:   We revealed gaps in understanding of  co-trimoxazole use among study participants. We therefore recom-
mend that more facts about co-trimoxazle as prophylaxis against P. jirovecii, bacterial and diarrheal pathogens should be 
incorporated in VCT fact sheets.
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Introduction
Co-trimoxazole  prophylaxis  among  children,  adults 
and  adolescents  living  with  HIV  has  been  the stand-
ard of  care for many years in high income countries 
as compared to resource-limited settings1. Co-trimox-
azole, a fixed dose combination of  sulfamethoxazole 
and trimethoprim, is abroad spectrum antimicrobial 
agent that targets a range of  aerobic gram-positive and 
gram-negative organisms, fungi and protozoa. Provid-
ing co-trimoxazole has been part of  the standard of  
care for preventing Pneumocystis jirovecii pneumonia 
and toxoplasmosis in the sub-Saharan Africa since 2000 
but the implementation has been slow2,3. Co-trimoxa-
zole prophylaxis has also been found to reduce mortal-
ity among patients on HAART4.
Studies in Mulago Hospital revealed that the prevalence 
of  HIV-infection among new tuberculosis cases de-
creased from 67% in 19895 to 19% in 20086. WHO es-
timates the burden of  TB/HIV co-infection at 19,836 
Ugandan adults in 20107.  Progressive drop of  CD4 T 
cells below 200 cells/µL increases the risks for oppor-
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tunistic infections like PCP8,9 and bacterial pneumonia 
10,11.
All HIV infected individuals are offered co-trimoxazole 
prophylaxis and this is in line with the WHO recom-
mendation1,12. Routine counseling and testing (RCT) is 
offered to every patient with confirmed tuberculosis13. 
In 2009, 17131 of  the 44335 (54%) TB cases in Uganda 
tested HIV positive of  whom 86% were initiated on 
co-trimoxazole chemoprophylaxis and 22% were start-
ed on HAART14. Co- trimoxazole is self-administered 
and therefore adherence cannot be ensured. The extent 
of  knowledge, attitudes and practice of  HIV  infected 
persons on co-trimoxazole is also unknown. This study 
was therefore undertaken to investigate co-trimoxazole 
use among HIV infected adults being evaluated for re-




As part of  a large study of  prevalence of  co-morbidity 
among HIV-infected recurrent PTB suspects15, we con-
ducted a qualitative cross sectional evaluation of  per-
ceptions about co-trimoxazole use.
Study setting
This study was conducted at the national referral tu-
berculosis treatment centre, Mulago National Refer-
ral and   Teaching Hospital, Kampala. Between 3500 
and 4500 tuberculosis patients (70 -75% new cases and 
25-30% recurrent cases) are treated annually at this TB 
treatment centre. Current statistics show that 19% of  
TB cases treated here are HIV co-infected6. New TB 
cases with HIV co-infection are treated with four anti-
tuberculosis drugs: isoniazid, rifampicin, pyrazinamide 
and ethambutol for two months of  intensive phase fol-
lowed by isoniazid and rifampicin for four months.
Study population and sample size
Five FGDs each consisting 6 participants (N=30) were 
conducted at the tuberculosis treatment center to deter-
mine the knowledge, attitudes and practices towards co-
trimoxazole use among people with HIV. HIV infected 
patients who presented with pulmonary symptoms of  
cough for two weeks or more being evaluated for re-
current tuberculosis were screened for Pneumocystis 
jirovecii infection. Other eligibility criteria included: (a) 
smear negative sputum for acid fast bacilli (AFB); (b) 
willingness and consent for participating in the study; 
(c) 18 years or older; (d) willingness and consent to un-
dergo induced sputum procedure.
Recruitment and data collection procedures
Participants were selected from a list of  those enrolled 
in the study aiming for equal representation by gender. 
They were contacted by cell phone and the next im-
mediate study participant was chosen if  the randomly 
selected one was unavailable. FGDs were conducted 
in English or Luganda (local dialect), the two most 
widely spoken languages in the study area. Two study 
staff  conducted each FGD lasting approximately one 
hour. FGDs were tape recorded and transcribed into 
MS Word. The domains covered were: participant`s 
knowledge and awareness of  co-trimoxazole use, per-
ceptions about who should be given  co-trimoxazole, 
whether HIV patients with  or without TB should take 
co-trimoxazole, relationship between HIV, TB and co-
trimoxazole, duration of  use, experiences taking co-tri-




This study was approved by the Makerere University 
Medical School Ethics and Research Committee and 
the Uganda National Council for science and Technol-
ogy. Written informed consent was obtained from all 
study participants
Results
The majority of  participants were males (57%) and their 
median ages was similar for both males 39 (IQR37-44) 
and for females 40 (IQR 32-44) years. There were also 
no significant differences in education, marital status 
and taking co-trimoxazole. Males (88%) compared to 
females (62%), reported being employed although this 
difference was not statistically significant (X2 test = 
2.93, p = 0.190). Meanwhilemore females (62%) com-
pared to males (42%) were taking ARVs although this 
was not statistically significant, (X2 test = 1.22, p = 
0.462). Of  note however, female participants had a sta-
tistically significant higher median CD4 T-cell counts 
of  457 (IQR 319-636)/L than males CD4 count of  207 
(IQR 38-451), p= 0.021 (Table 1).
Table 1: Clinical and socio-demographic characteristics of  study participants by gender, Mulago 
Hospital, Kampala Uganda
Characteristics                                            Gender
                                          Male n=17 (%)              Female n=13 (%)             X2 Test                 P-value
Employment status            15 (88)                             8   (62)                                2.93                   0.190
employed
Education                          13   (76)                            10   (77)                             0.01                   1.000
Not beyond primary level
Marital status                      14 (82)                             10 (77)                                                         1.000
married                               0.13
Median CD4 T-cell
count/L (IQR)                   207 (38-451)                    457(319-636)                      0.021                   7.03
Taking co-trimoxazole        13 (76)                             11 (85)                               0.672                  0.31
On ARV                             7    (41)                            8   (62)                               1.22                   0.462
Mean age (years)                 39(37-44)                         40(32-44)                           0.29                   0.715
There were no significant statistical differences in clinical and socio-demographic characteristics by gender except 
the median CD4 T-cell counts (X2 test =7.03, p=0.021).
Participant`s knowledge and awareness of  co-tri-
moxazole
All participants had ever heard about co-trimoxazole 
and reported to have used it to treat symptoms like 
cough at least once in their life time, as one participant 
noted:
“co-trimoxazole is everywhere in our hospitals and 
clinics so I think everyone has heard about co-trimox-
azole”. Co-trimoxazole appears to be widely available 
according to the participants. majority described co-
trimoxazole as an analgesic (Table 2). 
Table 2: Responses of  study participants on their understanding the term co-trimoxazole in Mulago
Hospital, Kampala Uganda.
Responses                                                                            Number of  times          Percentage
It is a pain killer                                                                      15                                       51.7
It is an antibiotic that treats any disease                                  2                                         6.9
It is any kind of  treatment                                                      1                                         3.5
A drug for cough and chest pain                                             1                                         3.5
A drug that protects us HIV-positive from other diseases       10                                       34.5
Total                                                                                       29                                       100
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Some participants reported co- trimoxazole to be medi-
cine given to those with decreased immunity to prevent 
them from getting opportunistic infections associated 
with HIV/AIDS. The quotes below further illustrates 
this observation:
“When they found out that I was HIV positive, health 
workers started me on co-trimoxazole and what they 
told me was co-trimoxazole is going to help in protect-
ing me from diseases like malaria, diarrhea and cough. 
So co-trimoxazole is medicine given to those with low 
immunity like me.”
Who should be given co-trimoxazole?
Majority of  participants believed that co-trimoxazole 
was for treatment of  HIV positive patients.
“Co-trimoxazole is always given to HIV positive pa-
tients to protect them from all illnesses since their bod-
ies are weak.” as one participant noted.
A few thought co-trimoxazole should be taken by any-
body regardless of  HIV status as one participant not-
ed:
“…. everyone should swallow co-trimoxazole whether 
HIV positive or not because we are told that co-trimox-
azole prevents the body from becoming weak….”
Should HIV patients with or without TB take co-
trimoxazole?
Majority of  patients believed co-trimoxazole use by 
HIV-infected persons is important since it prevents 
other opportunistic infections. For those participants 
who were co-infected with both TB and HIV, major-
ity noted that co-trimoxazole should be taken regard-
less of  the disease they had. Notably, some participants 
thought there is no need to take co-timoxazole because 
they perceived it and the TB drugs to treat the same 
diseases. Thus taking co-trimoxazole and anti-TB drugs 
would be wastage and an increase on the pill burden. 
One participant believed there is no need to take co-
trimoxazole with anti-TB drugs since health workers 
never instructed him to do so during the period he was 
on TB treatment although he is HIV infected as ex-
pressed below: 
 
“No, he/she should not take it because co-trimoxazole 
has nothing to do with TB. When I was found to have 
TB, health workers never instructed me to take co-tri-
moxazole. So I think this person should only take TB 
drugs and ARVs only.”
Relationship between HIV, TB and co-trimoxazole
Most respondents believed there is a link between HIV 
and TB, attributing this to the high prevalence of  TB 
among HIV infected patients as expressed below:
“Before I was HIV positive I used to hear about TB but 
after becoming HIV positive I developed TB and many 
of  my HIV positive colleagues in the clinic I attend de-
veloped TB. This therefore means TB is a common dis-
ease amongst us (HIV positive persons).”
Some respondents believed there is no relationship be-
tween the two diseases suggesting that TB is a disease 
which can affect both HIV infected and non-infected 
persons.
“Very many people out there have been diagnosed with 
TB yet they are not HIV positive so there is no link 
between TB and HIV because even those who are not 
HIV positives can also be affected by the disease.”
Should an HIV patient on anti-TB treatment also 
take co-trimoxazole?
Majority of  the participants reported that HIV patients 
on TB treatment could take co- trimoxazole with  anti-
TB drugs  attributing this  to  the  perceived preventive 
activity of   co- trimoxazole and reducing the incidence 
of  opportunistic infections among PLHIV. However, 
 some respondents believed even though co-trimoxazole 
is very important, the immune status of  the individual 
is critical in the decision to prescribe co-trimoxazole to 
someone as quoted below:
“…it depends on the strength of  the body because I 
was stopped from swallowing co- trimoxazole when I 
was taking TB medicine. The health workers told me 
my body may not withstand the strength of  both TB 
medicine and co-trimoxazole and I was left on TB med-
icine until the treatment was over then I resumed my 
co-trimoxazole.”
Notably, some respondents believed there is no need 
for HIV-infected patients to continue taking co-trimox-
azole along with TB drugs because they perceived both 
to contain the same active ingredients for treating chest 
infections.
Should HIV patients on ARVs also take co-trimox-
azole?
Majority of  the participants thought it was important 
for a patient to take co-trimoxazole and ARVs simul-
taneously. Respondents believed that co-trimoxazole 
would continue protecting the body from other diseases 
as reported below:
“It is very important for an HIV patient to continue 
with co-trimoxazole although he/she is swallowing 
ARVs. For example; I was put on ARVs but I was en-
couraged by the health workers to continue with co-tri-
moxazole because co-trimoxazole was to prevent other 
diseases like diarrhea which may affect my body and am 
now fine.”
Some respondents felt it is not necessary for HIV in-
fected persons to continue with co- trimoxazole. They 
believed that ARVs are as  effective as  co-trimoxazole. 
Thus if  an HIV infected person were to continue with 
the two kinds of  medicine, this would be increasing 
their pill burden.
For how long should one take co-trimoxazole?
Majority of  the participants never knew for how long 
one should take co-trimoxazole. Some believed co-tri-
moxazole should be taken as a lifelong treatment. While 
others thought that health care workers should deter-
mine the duration.
“I know we are supposed to take co-trimoxazole for-
ever. But I think at one moment my health workers may 
decide to put me off  this medicine especially when my 
CD4 cells have gone high because the same thing was 
done to my friend and she is now fine,” as explained by 
one participant.
On the other hand, some participants believed that 
someone should stop taking co-trimoxazole if  he or she 
develops side effects particularly when the side effects 
are severe and can lead to death as expressed below:
“When I was started on co-trimoxazole a few days later 
I developed a very severe skin rash and burns all over 
the body and after talking to the health workers, they 
decided to stop me and instead I  was given another 
medicine (dapsone) which I am currently using.”
Notably, some participants believed a patient could stop 
at any time he/she feels better. 
 
Experiences with co-trimoxazole
All participants reported improvement in their quality 
of  life after taking co-trimoxazole, as shown by signifi-
cant reduction in pain and incidences of  opportunistic 
infections. However, some respondents expressed the 
view that despite perceived improvement in their lives, 
they still face a challenge of  taking co-trimoxazole every 
day as this is cumbersome.
“Co-trimoxazole has improved our lives, for example 
I used to feel weak, headache and fevers but currently 
I am fine. However, this does not mean that it is easy 
to swallow co- trimoxazole regularly. Imagine every day 
I must swallow two tablets; for sure this makes it very 
cumbersome.”
Side effects of  co-trimoxazole
Majority of  the participants had not experienced side-
effects of  co-trimoxazole although they heard from 
their friends. The commonest side effects heard includ-
ed skin rash, itching of  the body and burning sensa-
tions in the stomach. Many of  respondents, who had 
not experienced side-effects of  co-trimoxazole thus far, 
expressed their fear of  risks of  adverse events of  co- 
trimoxazole in future they believed as a consequence of  
its long term use.
What happens if  co-trimoxazole is not taken every 
day?
Most participants believed that it is not good to stop 
taking co-trimoxazole. They believed that without co-
trimoxazole, opportunistic diseases will infect them and 
this will increase the incidences of  morbidity and pos-
sibly mortality among them. The quote below illustrates 
this perception. 
 
“‘I have seen  many of   my  colleagues, who stopped 
swallowing co-trimoxazole and developed diseases and 
later died.”
Discussion
The study established that all participants had ever heard 
about co-trimoxazole and majority had taken it. Major-
ity demonstrated that co-trimoxazole prevents oppor-
tunistic infections among HIV infected individuals with 
low immunity. They also indicated that HIV and TB 
were linked, and co-trimoxazole could be used concur-
rently with anti-tuberculosis medications and HAART. 
Most respondents were also aware of  the need for daily 
use. Similarly, most had ever heard of  side effects of  
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co-trimoxazole and were aware that treatment had to 
be discontinued if  side effects events were experienced. 
However there were mixed views about duration of  
co- trimoxazole use. Some participants believed that 
co-trimoxazole use was lifelong treatment while others 
believed health care workers determined the duration. 
In this study, the significantly low CD4 T-cell counts 
among males may imply that they present to health care 
facilities late andtherefore more likely to be very sick. 
Moreover in the main study (15), 8.3% (8/96) of  males 
had P.jirovecii as compared to 4.9% (4/82) female al-
though this study was not designed to address this as-
pect of  the finding. Further studies in this setting show 
that males have generally poorer health seeking behav-
ior compared to females24,25.
Despite overall wide knowledge, few respondents had 
important knowledge gaps and misconceptions result-
ing from real life experiences of  co-trimoxazole use. 
For example, some participants perceived co-trimoxa-
zole as an analgesic. Others believed that co-trimoxa-
zole is exclusively for HIV-infected people. The later 
belief  is quite positive for encouraging the use of  co-
trimoxazole by HIV–infected individuals. The benefit 
of  this is consistent with findings of  one study con-
ducted in Uganda and Zimbabwe4. There were divided 
views among participants whether or not to administer 
co-trimoxazole to HIV infected patients taking both 
HAART and anti-tuberculosis drugs. Those partici-
pants who support concurrent use of  co-trimoxazole 
believe that co-trimoxazole does reduce the incidents 
of  opportunistic infections among PLHIV. This shared 
view is encouraging and consistent with WHO rec-
ommendations on use of  co-trimoxazole by PLHIV1. 
Similarly, several studies have shown that  prophylaxis 
with co- trimoxazole reduced mortality in HIV positive 
adults with confirmed tuberculosis16-19.
Those who disagree with concurrent use of  co-trimox-
azole by PLHIV on both HAART and anti- tubercu-
losis therapy argue that anti-tuberculosis drugs work 
like co-trimoxazole, hence it is inappropriate to take it. 
Anti-tuberculosis drugs including rifampicin, isoniazid, 
ethambutol, streptomycin and pyrazinamide are used to 
treat active tuberculosis. This means that these drugs 
are active mainly against M. tuberculosis microorgan-
isms that cause tuberculosis disease than other  oppor-
tunistic  diseases.  Meanwhile  co-trimoxazole is  used 
to  prevent  and  treat  other opportunistic diseases such 
as bacterial pneumonia, Pneumocystis jirovecii pneu-
monia, toxoplasmosis, Isospora beri diarrhea and non-
typhoidal salmonelosis among PLHIV20-23. Therefore if  
these participants stopped taking co-trimoxazole, the 
risks of  infection with opportunistic pathogens, inci-
dence of  opportunistic diseases and mortality would 
increase among them19. A well designed information, 
education and communication (IEC) package needs to 
be put in place by the MoH as an intervention strategy 
to address this misconception and knowledge gaps. 
 
Although majority of  participants thought that co-tri-
moxazole should be taken by all HIV- infected people 
on HAART, there was significant misconception that 
co-trimoxazole should not be taken for long because 
HAART works like co-trimoxazole. These knowledge 
gaps would likely contribute to low co-trimoxazole ad-
herence which can lead to increase of  opportunistic 
diseases.
There has been evolving guidelines on when to stop 
co-trimoxazole prophylaxis. Previous WHO guidelines 
recommend that co-trimoxazole prophylaxis can be 
stopped if  one is on HAART and CD4 is above 200 
cells/µL for 6 months1. Meanwhile the ministry of  
health (MoH) guideline recommends co-trimoxazole 
prophylaxis for life in the absence of  HAART, but in-
conclusive for patients on HAART and CD4 count>200 
cells/µL13. Although some study participants expressed 
the view that co-trimoxazole prophylaxis has improved 
their health by reducing the incidences of  opportunistic 
infections, many of  them face challenges. One of  the 
biggest challenges is adherence to long term medica-
tion. In this study, the following factors were identified 
as  contributing to  negative influence on  adherence: 
cumbersomeness to  take  co- trimoxazole  daily,  side 
effects  of   co-trimoxazole and  advice  from  relatives 
to  discontinue administration   of    co-trimoxazole. 
Low   adherence   to   co-trimoxazole   increases   risk 
of  development of  resistance by microorganisms. Giv-
en the emergence of  resistance to trimethoprim-sulfa-
metoxazole among many bacteria26, and a more recent 
study that found co- trimoxazole resistance to Strepto-
coccus pneumonia of  91% and to non-typhoidal sal-
monella of  67%27, concern has focused on the potential 
development of  resistant Pneumocystis. In the Uganda 
context, co-trimoxazole is widely available in the coun-
try. Studies on use of  medicines especially antibiotics 
use in Uganda28 show that, drugs including antibiotics, 
are widely available over the counter with or without 
prescriptions in pharmacies and most drug shops. We 
also have drug hawkers within the public commuter taxi 
parks and bus stations who likewise advise patients on 
what medication to take including antibiotics29. These 
situations may lead to irrational use of  antibiotics in-
cluding co-trimoxazole. The prescription practices by 
clinicians in Uganda may also encourage irrational an-
tibiotic use despite the existence of  national standard 
treatment guidelines on rational drug use30,31. In terms 
of  administration of  co-trimoxazole concurrently with 
anti-tuberculosis therapy in HIV co-infection with TB, 
majority of  the participants believed that co-trimoxa-
zole should be taken since it prevents other diseases. 
This particular belief  is very positive because it encour-
ages co-trimoxazole use among them.
The study draws strength from use of  FGDs because 
they were helpful in interpreting previously obtained 
quantitative results and diagnosing the potential prob-
lems with a new programmme or service: the number 
of  participants on co-trimoxazole and co-trimoxazole 
role out programme, in this case. 
Limitations
Limitations of  the study include the following:   selec-
tion of  respondents was not stratified by duration of  
HIV infection, co-trimoxazole and HAART use. And 
patients with recurrent PTB are likely to have persis-
tent coughs and coughs due to viral pathogens, making 
it hard to appreciate the role of  co-trimoxazole in im-
proving their quality of  life. 
 
Conclusion
There are information gaps in the use of  co-trimox-
azole among study participants. The belief  that HIV 
infected adults can stop taking co-trimoxazole at any 
time could lead to low adherence. Females had statis-
tically significantly higher median CD4 T-cell counts 
than males. For policy and practice, the following rec-
ommendations are therefore proposed: as part of  a 
comprehensive HIV Health Care package,all HIV and 
TB clinics should have IEC materials that address ben-
efits of  co-trimoxazole prophylaxis and warning signs 
of  side effects, adherence, concurrent use with other 
medications like HAART, anti-tuberculosis drugs and 
drugs that treat other opportunistic infections. 
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